Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons.

Slides:



Advertisements
Similar presentations
Date of download: 5/30/2016 From: Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium Ann Intern Med. 2000;132(9):
Advertisements

Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response  Henry Lik–Yuen Chan, Vincent.
A Proton Pump Inhibitor a Day Keeps the Iron Away
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B  Emmet B. Keeffe, Stefan Zeuzem,
Volume 130, Issue 3, Pages (March 2006)
Abnormal Liver Tests and Fatty Liver on Ultrasound
Thrombocytopenia With Abnormal Liver Function Tests
Introduction to Genetic Analysis
Volume 145, Issue 2, Pages (August 2013)
Incorrect Calculation and Inappropriate Interpretation: Accuracy of International Guidelines for Identifying Significant Fibrosis in e Antigen–Negative.
Ruben Hernaez, MD, MPH, PhD  Clinical Gastroenterology and Hepatology 
Muscle Cramps in Cirrhosis: A Moving Target
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update  Emmet B. Keeffe, Douglas T. Dieterich,
Pichamol Jirapinyo, Christopher C. Thompson 
Uchenna H. Iloeje, Hwai–I
Volume 130, Issue 3, Pages (March 2006)
Effectiveness of Hepatitis B Treatment in Clinical Practice
mRNA Trafficking and Local Protein Synthesis at the Synapse
Mechanisms of HBV-related hepatocarcinogenesis
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Volume 133, Issue 3, Pages (September 2007)
How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?  Neil Rajoriya,
Fasiha Kanwal, MD, MSHS, Hashem B. El-Serag, MD, MPH 
Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B  Emmet B. Keeffe, Stefan Zeuzem,
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Volume 44, Issue 5, Pages (May 2006)
Volume 68, Issue 3, Pages (March 2018)
Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H
Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay?  Brian J. McMahon, MD, Brenna C. Simons, PhD  Clinical.
Chronic Hepatitis B: Current Testing Strategies
Occult hepatitis B infection
Metabolic Inputs into the Epigenome
DCo(H2)ding the Metabolic Functions of SIRT1 in the Intestine
Timothy M. Block, Ju-Tao Guo  Gastroenterology 
A Proton Pump Inhibitor a Day Keeps the Iron Away
Abnormal Liver Tests and Fatty Liver on Ultrasound
Hepatitis B cure: From discovery to regulatory approval
Gastroenterology in a New Era of Accountability: Part 2
Epigenetics: A Landscape Takes Shape
Volume 42, Issue 3, Pages (March 2005)
Nicholas D Weber, Daniel Stone, Keith R Jerome  Molecular Therapy 
Epigenetics modification
The role of quantitative hepatitis B surface antigen revisited
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update  Emmet B. Keeffe, Douglas T. Dieterich,
Peter Bytzer  Clinical Gastroenterology and Hepatology 
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
Lost in Translation: An Antiviral Plant Defense Mechanism Revealed
Alan Bonder, MD, Nezam H. Afdhal, MD 
Suna Yapali, MD, Anna S. Lok, MD, FRCP 
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 55, Issue 5, Pages (November 2011)
Figure 2 Histone acetylation regulates gene expression
Basic concepts of epigenetics
Environmental epigenetics of asthma: An update
Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response  Henry Lik–Yuen Chan, Vincent.
Hepatic Cyst? Clinical Gastroenterology and Hepatology
Epigenetic modifications as new targets for liver disease therapies
Thrombocytopenia With Abnormal Liver Function Tests
Christos Konstantakis, Maria Karamesini, Christos Triantos 
Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States  Zobair M. Younossi, Maria Stepanova 
Retrovirus Silencing by an Epigenetic TRIM
A 27-Year-Old Woman With Constipation: Diagnosis and Treatment
Management of Hepatitis B
Volume 156, Issue 3, Pages (February 2019)
Coagulation in Liver Disease: A Guide for the Clinician
Transcriptional Scaffolds for Heterochromatin Assembly
Medical Therapy for Refractory Pediatric Crohn’s Disease
Epigenetics.
Presentation transcript:

Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons From Experimental and Clinical Studies  Fabien Zoulim, MD, PhD, Barbara Testoni, PhD, Fanny Lebossé, MD  Clinical Gastroenterology and Hepatology  Volume 11, Issue 8, Pages 1011-1013 (August 2013) DOI: 10.1016/j.cgh.2013.04.010 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 HBsAg synthesis and cccDNA dynamics during HBV infection. HBsAg is produced from cccDNA and HBV sequences integrated in the host genome. Then, HBs is secreted as a component of complete virions, as well as filamentous and spherical particles. NUC-based treatment interferes with viral polymerase activity and recycling of newly synthesized relaxed, circular, partially double-stranded DNA (rcDNA) into the cell nucleus, ultimately affecting both virion productivity and cccDNA pool amplification. Viral cccDNA is organized as a minichromosome and its transcriptional activity is regulated epigenetically, which in turn may affect HBsAg expression levels. IFN-based treatments favor the recruitment of negative regulators, determining a cccDNA silenced chromatin status, not permissive to active transcription and expression of viral proteins. When the liver is subjected to injury/regeneration cycles, hepatocyte turnover contributes to the dilution of cccDNA content, but it does not affect HBV-integration events, which continue to represent a potential source of HBsAg production. ESCRT, endosomal sorting complexes required for transport; DNMT, DNA methyl-transferase; HAT, histone acetyl-transferase; HBc, HBV Core protein; HBx, HBV X protein; HDAC, histone deacetylase; HMT, histone methyl-transferase; HP1, heterochromatin protein 1; MeCP2, methyl CpG binding protein 2; mRNA, messenger RNA; MVB, multi-vesicular bodies; PCAF, p300/CREB-binding protein-associated factor; Sirt1, human Silent Information Regulator, sirtuin; Suv39, Histone H3-K9 Methyltransferase ESET; TF, transcription factor. Clinical Gastroenterology and Hepatology 2013 11, 1011-1013DOI: (10.1016/j.cgh.2013.04.010) Copyright © 2013 AGA Institute Terms and Conditions